Pharma Blog
Pulmonary Embolism | A Life-Threatening Condition
As a professional pharmacist, it’s critical to shed light on Pulmonary Embolism (PE), a serious condition that can be life-threatening if not promptly treated. What is Pulmonary Embolism? PE occurs when a blood clot travels to the lungs, blocking one or more pulmonary arteries. This blockage can severely impair lung ... Read More
Difference Among Assay on As is Basis, on Dried Basis and on Anhydrous Basis
A. Assay on an As is basis refers to the measurement of the content of a substance in its original state, without any removal of water or other volatile components. This type of assay is used when the presence of water or other volatile components does not affect the accuracy ... Read More
A Comprehensive Comparison between ANDA (Generics) and Biosimilars
Composition ANDA (Generics): Biosimilars: Approval Process ANDA (Generics): Biosimilars: Manufacturing Challenges ANDA (Generics): Biosimilars: Regulation ANDA (Generics): Biosimilars: Market ANDA (Generics): Biosimilars: Analytical Validation ANDA (Generics): Biosimilars: Process Validation ANDA (Generics): Biosimilars: Supply Chain ANDA (Generics): Biosimilars: Read also:
Basics of Tablet Tooling
Tooling can be defined as tools to craft a particular shape. Tableting tools i.e., Punches and dies are essential tools to shape any granules into a solid dosage form by applying compaction force in a compression machine. Any shape be it round, oblong or bullet shape or any special shape ... Read More
Purpose of Tablet Coating
Tablets are the most commonly used dosage form which are manufactured in Pharmaceutical Industries. Many tablets in pharma are coated and some tablets are uncoated. Tablet coating is the process where we apply a thin coat of film formers & related excipients over the tablet surface. REASONS FOR TABLET COATING ... Read More
Facility Readiness Goal Date Decisions Under GDUFA
The Generic Drug User Fee Amendments (GDUFA) aim to streamline the approval process for generic drugs, ensuring timely access to affordable medications. A crucial aspect of this process is the Facility Readiness Goal Date Decisions, which influence the FDA’s timelines for reviewing and approving generic drug applications. Key Highlights from ... Read More
FDA Non-Clinical Study Requirements for IND
Non-clinical studies are essential for assessing the safety and biological activity of an investigational drug before it is tested in humans. Here are the key aspects and requirements for non-clinical studies in an IND application: Pharmacology and Toxicology Information Non-clinical studies primarily focus on pharmacology and toxicology to evaluate the ... Read More
FDA Clinical Study Requirements for IND
Clinical study requirements for an Investigational New Drug (IND) application are designed to ensure the safety and efficacy of the investigational drug during human trials. Here are the key aspects and requirements: Clinical Study Protocol A detailed clinical study protocol must be included in the IND application. This protocol should ... Read More
Administrative Modules and Submission of IND Application
The administrative module of an IND application includes essential forms and information that provide the FDA with details about the sponsor, the investigational drug, and the proposed clinical trials. Key components include: Submission The submission of an IND application involves several steps to ensure that the FDA receives all necessary ... Read More
Types and Components of Investigational New Drugs (IND) Application
An Investigational New Drug (IND) application is a request for authorization from the FDA to administer an investigational drug or biological product to humans. This application must be authorized before the interstate shipment and administration of any new drug or biological product that is not the subject of an approved ... Read More